Suppr超能文献

采用去除T淋巴细胞的HLA单倍型不相合骨髓移植治疗重症联合免疫缺陷后的重建。

Reconstitution after transplantation with T-lymphocyte-depleted HLA haplotype-mismatched bone marrow for severe combined immunodeficiency.

作者信息

Reinherz E L, Geha R, Rappeport J M, Wilson M, Penta A C, Hussey R E, Fitzgerald K A, Daley J F, Levine H, Rosen F S, Schlossman S F

出版信息

Proc Natl Acad Sci U S A. 1982 Oct;79(19):6047-51. doi: 10.1073/pnas.79.19.6047.

Abstract

Severe combined immunodeficiency (SCID) is potentially correctable by bone marrow transplantation if a patient has a suitable histocompatible donor. In the absence of an HLA-matched donor, lethal graft-versus-host disease (GVHD), which is mediated by alloreactive donor T cells, may occur. In an attempt to prevent GVHD in one SCID patient lacking a matched donor, we treated maternal haplomismatched bone marrow with a unique nonmitogenic T-cell-specific monoclonal antibody (anti-T12) and complement to remove mature T cells. Despite the removal of greater than 99% mature T cells, the child developed significant life-threatening GVHD, which was terminated by a 5-day course of intravenous anti-T12. Subsequently, immune reconstitution occurred by 6 wk: the mature circulating T cells proliferated in response to soluble and allo-antigens in vitro and provided help for B-cell immunoglobulin synthesis. The patient was removed from a protective environment and discharged without evidence of further infection. Both HLA and chromosomal analyses showed that the circulating cells in the patient were of maternal origin. More importantly, the maternal T cells were no longer reactive with recipient cells. Mixing experiments indicated that the state of tolerance that resulted in this chimera was not due to active suppression. We conclude that HLA-mismatched transplantation for SCID can be undertaken if mature alloreactive donor T lymphocytes are depleted before and after bone marrow grafting.

摘要

如果患者有合适的组织相容性供体,严重联合免疫缺陷(SCID)可通过骨髓移植得到潜在纠正。在没有HLA匹配供体的情况下,可能会发生由同种异体反应性供体T细胞介导的致死性移植物抗宿主病(GVHD)。为了在一名缺乏匹配供体的SCID患者中预防GVHD,我们用一种独特的非促有丝分裂T细胞特异性单克隆抗体(抗-T12)和补体处理母体单倍体不匹配的骨髓,以去除成熟T细胞。尽管去除了超过99%的成熟T细胞,但患儿仍发生了严重的危及生命的GVHD,通过5天的静脉注射抗-T12疗程得以终止。随后,6周时出现免疫重建:成熟的循环T细胞在体外对可溶性和同种异体抗原产生增殖反应,并为B细胞免疫球蛋白合成提供帮助。患者从保护环境中移出并出院,没有进一步感染的迹象。HLA和染色体分析均显示患者体内的循环细胞来自母体。更重要的是,母体T细胞不再与受体细胞发生反应。混合实验表明,导致这种嵌合体的耐受状态并非由于主动抑制。我们得出结论,如果在骨髓移植前后去除成熟的同种异体反应性供体T淋巴细胞,就可以进行SCID的HLA不匹配移植。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d281/347049/9437e578307f/pnas00458-0299-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验